Helix Biopharma (HBPCF) Stock Price, News & Analysis

Company Overview

Helix BioPharma Corp. is a Canadian biotechnology company focused on developing novel therapies for cancer. Its research has centered on targeted treatments intended to address the tumor microenvironment and improve the delivery or effectiveness of anticancer agents.

The company’s principal investigational product has been L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. The treatment is intended to alter the acidic conditions surrounding tumors, which may help create an environment less favorable to cancer-cell growth. Helix has investigated L-DOS47 in cancers including pancreatic cancer and non-small cell lung cancer.

Helix BioPharma is headquartered in Canada and has conducted its drug-development activities through international clinical and research programs. As a clinical-stage biotechnology company, its products have primarily remained in development rather than being marketed as commercially available medicines.

Key Stats

• Today's Range: $1.71 to $1.71
• 50-Day Range: $1.71 to $1.71
• 52-Week Range: $1.71 to $1.73
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $130.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 6/12/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:HBPCF
• CIK: N/A
• Web: www.helixbiopharma.com
• Phone: 905-841-2300
• Fax: 905-841-2244
• Employees: 9
• Year Founded: 1995

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.61%
• Return on Assets: -17.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.45
• Quick Ratio: 0.45

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 11.40

Miscellaneous

• Outstanding Shares: 76,380,000
• Free Float: 70,573,000
• Market Cap: $130.61 million
• Optionable: Not Optionable
• Beta: 0.18